Saunders Catherine L, Meads Catherine, Abel Gary A, Lyratzopoulos Georgios
Catherine L. Saunders and Georgios Lyratzopoulos, Cambridge Centre for Health Services Research, University of Cambridge; Catherine Meads, Anglia Ruskin University, Cambridge; Gary A. Abel, University of Exeter Medical School, Exeter; and Georgios Lyratzopoulos University College London, London, United Kingdom.
J Clin Oncol. 2017 Nov 10;35(32):3654-3661. doi: 10.1200/JCO.2017.72.5465. Epub 2017 Sep 25.
Purpose To address gaps in evidence on the risk of cancer in people from sexual minorities. Patients and Methods We used data from 796,594 population-based English General Practice Patient Survey responders to explore the prevalence of self-reported diagnoses of cancer in the last 5 years among sexual minorities compared with heterosexual women and men. We analyzed data from 249,010 hospital-based English Cancer Patient Experience Survey responders with sexual orientation as a binary outcome, and International Classification of Diseases, Tenth, Revision, diagnosis as covariate-38 different common and rarer cancers, with breast and prostate cancer as baseline categories for women and men, respectively-to examine whether people from sexual minorities are over- or under-represented among different cancer sites. For both analyses, we used logistic regression, stratified by sex and adjusted for age. Results A diagnosis of cancer in the past 5 years was more commonly reported by male General Practice Patient Survey responders who endorsed gay or bisexual orientation compared with heterosexual men (odds ratio [OR], 1.31; 95% CI, 1.15 to 1.49; P < .001) without evidence of a difference between lesbian or bisexual compared with heterosexual women (OR, 1.14; 95% CI, 0.94 to 1.37; P = .19). For most common and rarer cancer sites (30 of 33 in women, 28 of 32 in men), the odds of specific cancer site diagnosis among Cancer Patient Experience Survey respondents seemed to be independent of sexual orientation; however, there were notable differences in infection-related (HIV and human papillomavirus [HPV]) cancers. Gay or bisexual men were over-represented among men with Kaposi's sarcoma (OR, 48.2; 95% CI, 22.0 to 105.6), anal (OR, 15.5; 95% CI, 11.0 to 21.9), and penile cancer (OR, 1.8; 95% CI, 0.9 to 3.7). Lesbian or bisexual women were over-represented among women with oropharyngeal cancer (OR, 3.2; 95% CI, 1.7 to 6.0). Conclusion Large-scale evidence indicates that the distribution of cancer sites does not vary substantially by sexual orientation, with the exception of some HPV- and HIV-associated cancers. These findings highlight the importance of HPV vaccination in heterosexual and sexual minority populations.
目的 填补关于性少数群体患癌风险证据方面的空白。患者与方法 我们使用了来自796,594名参与基于人群的英国全科医疗患者调查的应答者的数据,以探究性少数群体中自我报告的过去5年癌症诊断患病率,并与异性恋女性和男性进行比较。我们分析了来自249,010名参与基于医院的英国癌症患者体验调查的应答者的数据,将性取向作为二元结局,以国际疾病分类第十版诊断作为协变量——38种不同的常见和罕见癌症,分别将乳腺癌和前列腺癌作为女性和男性的基线类别——以检查性少数群体在不同癌症部位的代表性是过高还是过低。对于这两项分析,我们使用了逻辑回归,按性别分层并对年龄进行了调整。结果 在过去5年中,与异性恋男性相比,认可同性恋或双性恋取向的男性全科医疗患者调查应答者更常报告患癌情况(优势比[OR],1.31;95%置信区间[CI],1.15至1.49;P <.001),而女同性恋或双性恋女性与异性恋女性之间没有差异(OR,1.14;95% CI,0.94至1.37;P =.19)。对于大多数常见和罕见癌症部位(女性33个中的30个,男性32个中的28个),癌症患者体验调查应答者中特定癌症部位诊断的几率似乎与性取向无关;然而,在与感染相关(HIV和人乳头瘤病毒[HPV])的癌症方面存在显著差异。在患有卡波西肉瘤(OR,48.2;95% CI,22.0至105.6)、肛门癌(OR,15.5;95% CI,11.0至21.9)和阴茎癌(OR,1.8;95% CI,0.9至3.7)的男性中,同性恋或双性恋男性的比例过高。在患有口咽癌的女性中,女同性恋或双性恋女性的比例过高(OR,3.2;95% CI,1.7至6.0)。结论 大规模证据表明,除了一些与HPV和HIV相关的癌症外,癌症部位的分布在性取向上没有显著差异。这些发现凸显了HPV疫苗接种在异性恋和性少数群体中的重要性。